Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Nero who wrote (718)	5/6/1998 3:46:00 AM
From: SnowShredder	Read Replies (3) \| Respond to of 2135

Nero, Sorry to hear about your misfortune. B 4 you go long til 2002 I suggest that you take a look @ the November 7, 1997 issue of Science. The article "Systems for Identifying New Drugs Are Often Faulty" by Trisha Gura that talks about some of the problems using model systems (eg. mice) for testing anticancer drugs. Best of luck, Where'd He Go?

To: Nero who wrote (718)	5/6/1998 4:20:00 AM
From: Haolin Ni	Read Replies (1) \| Respond to of 2135

Hi, Nero, I am sorry to hear your sad story. You should not compare ENMD with KTEL. Rarely, Biotech stocks have short squeeze if not all because the biothech companies need long time to generate any good news and the big share floating. There are too many biotech companies are developing cancel cure drugs and no one can say for sure which one will be success. Check the big run up of other biotech companies such as GERN, ONXX, AVIR, etc etc. There are so many longs losing big in stock price run up and they will get out when the pain is unbearable or margin call coming. KTEL is pushing their price but ENMD and Bristol-Myers are not doing so. Sell you shares now then buy them back at lower price if you really belive ENMD or want to gamble on it. Then, you can claim lose and wait for your profit to come one day. Best regards!